Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Cash from Financing Activities (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Cash from Financing Activities for 7 consecutive years, with $3.5 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Cash from Financing Activities rose 96.64% year-over-year to $3.5 million, compared with a TTM value of $19.4 million through Dec 2019, down 71.01%, and an annual FY2024 reading of $161.9 million, up 539510.0% over the prior year.
  • Cash from Financing Activities was $3.5 million for Q4 2019 at Larimar Therapeutics, down from $10.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $129.6 million in Q1 2015 and bottomed at -$756000.0 in Q4 2016.
  • Average Cash from Financing Activities over 5 years is $11.5 million, with a median of $38500.0 recorded in 2018.
  • The sharpest move saw Cash from Financing Activities crashed 22900.0% in 2015, then surged 32850.0% in 2019.
  • Year by year, Cash from Financing Activities stood at -$684000.0 in 2015, then decreased by 10.53% to -$756000.0 in 2016, then soared by 2577.51% to $18.7 million in 2017, then crashed by 90.62% to $1.8 million in 2018, then skyrocketed by 96.64% to $3.5 million in 2019.
  • Business Quant data shows Cash from Financing Activities for LRMR at $3.5 million in Q4 2019, $10.0 million in Q3 2019, and $5.9 million in Q2 2019.